Effect of dead volume on the efficiency and the cost to deliver medications in cystic fibrosis with four disposable nebulizers.
OBJECTIVE
To evaluate the factors that affect nebulizer efficiency and to compare the relative cost effectiveness of nebulized medications used in the treatment of cystic fibrosis (CF), delivered by four types of disposable jet nebulizers that are widely used in hospitals.


METHODS
The Hudson 1730 Updraft II, Baxter Misty-Neb, Marquest Whisper Jet (WJ), and Marquest Acorn II were evaluated in terms of respirable aerosol output (particles 5 microm or less), nebulizer dead (residual) volume (VD), and time for complete nebulization using saline, salbutamol and tobramycin at flows of 6 and 8 L/min. The respirable fraction (RF) was determined by laser diffraction, and drug output was calculated from the initial volume and concentration of the drug in the nebulizer minus the product of final drug concentration and the VD following nebulization.


METHODS
The expected pulmonary deposition (DE) was estimated, and incorporated with the material and labour costs to determine the cost effectiveness of each type of nebulizer.


RESULTS
With a DE greater than two times that of the WJ at a cost of 2.4 times less, the Updraft II proved most efficient and cost effective of all the nebulizers evaluated in this study.


CONCLUSIONS
The cost effectiveness of each nebulizer was determined by its efficiency, which in turn was predominantly related to its VD and RF at each flow. The efficiencies of these four devices were different and could not have been predicted from specifications provided by the respective manufacturers.
The Hospital for Sick Children, Research Institute, and the University of Toronto, Toronto, Canada.
S L
SL
Ho
A L
AL
Coates
D000280:Administration, Inhalation; D000420:Albuterol / Q000008:administration & dosage; D002170:Canada; D016001:Confidence Intervals; D003362:Cost-Benefit Analysis; D003550:Cystic Fibrosis / Q000188:drug therapy*; D003625:Data Collection; D004209:Disposable Equipment / Q000191:economics*; D004867:Equipment Design; D005260:Female; D006801:Humans; D008297:Male; D009330:Nebulizers and Vaporizers / Q000191:economics*; D012126:Respiratory Dead Space / Q000187:drug effects / Q000502:physiology; D012680:Sensitivity and Specificity; D012965:Sodium Chloride / Q000008:administration & dosage; D014031:Tobramycin / Q000008:administration & dosage
D012965:Sodium Chloride; D000420:Albuterol; D014031:Tobramycin